"$ACUR approved" at 8:46 pm EDT after getting an email confirmation from FDA spokeswoman Riley. Oxecta is the first immediate-release opioid approved for the relief of moderate-to-severe pain that is also designed to deter common methods of misuse and abuse. The "typical" patient for such a drug would be someone who just had root canal or some other type of surgery and needs a painkiller for a short period of time -- a few days or up to one month. Relatively cheap generic drugs currently dominate the market for short-acting opioid pain relievers, so Pfizer and Acura will need the drug's label to adequately describe Oxecta's tamper resistance in order to justify premium pricing. Extended release, or long-acting, opioids that also aim to deter abuse are already on the market for patients who suffer from chronic pain. Purdue Pharma sells a tamper-resistant form of its popular Oxycontin. Pfizer and Pain Therapeutics ( PTIE) expect an FDA approval decision on June 23 for Remoxy, another long-acting abuse-resistant opioid. Acura has been trying to get Oxecta, then known as Acurox, approved since January 2009. The FDA first rejected the drug in June 2009. In April 2010, an FDA advisory panel voted against recommending the drug's approval. Acura and King Pharmaceuticals reformulated Oxecta/Acurox and resubmitted it for approval in December 2010. Later, Pfizer acquired King and took over marketing responsibilities for the Acura partnership. Pfizer will pay royalties ranging from 5% to 25% to Acura, based on levels of sales of Oxecta and other drugs included in the partnership. -- Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com.